73 related articles for article (PubMed ID: 23127933)
1. [Molecular entities of the breast cancer: the difference is in the origin].
Charafe-Jauffret E; Ginestier C
Ann Pathol; 2012 Nov; 32(5 Suppl):S35-6. PubMed ID: 23127933
[No Abstract] [Full Text] [Related]
2. Breast cancer intra-tumor heterogeneity.
Martelotto LG; Ng CK; Piscuoglio S; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2014 May; 16(3):210. PubMed ID: 25928070
[TBL] [Abstract][Full Text] [Related]
3. Is ALDH1 a good method for definition of breast cancer stem cells?
Neumeister V; Rimm D
Breast Cancer Res Treat; 2010 Aug; 123(1):109-11. PubMed ID: 19946740
[No Abstract] [Full Text] [Related]
4. Breast cancer stem cells: initiating a new sort of thinking.
Herschkowitz JI
Dis Model Mech; 2010; 3(5-6):257-8. PubMed ID: 20427552
[No Abstract] [Full Text] [Related]
5. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
6. Insights into the cell of origin in breast cancer and breast cancer stem cells.
Lindeman GJ; Visvader JE
Asia Pac J Clin Oncol; 2010 Jun; 6(2):89-97. PubMed ID: 20565420
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
8. Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.
Koren S; Bentires-Alj M
Mol Cell; 2015 Nov; 60(4):537-46. PubMed ID: 26590713
[TBL] [Abstract][Full Text] [Related]
9. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in breast cancer.
Vivanco Md
Methods Mol Biol; 2010; 593():137-56. PubMed ID: 19957148
[TBL] [Abstract][Full Text] [Related]
11. Biological progression of breast cancer and clinical implications.
Vici P; Sergi D; Pizzuti L; Vincenzoni C; Baiocco E; Mancini E; Lopez M; Vizza E; Lauro LD
Clin Ter; 2011; 162(4):297-9. PubMed ID: 21912815
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
14. [Breast cancer stem cells].
Yasuda K; Hirohashi Y; Torigoe T
Nihon Rinsho; 2012 Sep; 70 Suppl 7():76-83. PubMed ID: 23350369
[No Abstract] [Full Text] [Related]
15. Heterogeneity of breast cancer: etiology and clinical relevance.
Almendro V; Fuster G
Clin Transl Oncol; 2011 Nov; 13(11):767-73. PubMed ID: 22082639
[TBL] [Abstract][Full Text] [Related]
16. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells.
Cho JA; Park H; Lim EH; Lee KW
Int J Oncol; 2012 Jan; 40(1):130-8. PubMed ID: 21904773
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
[TBL] [Abstract][Full Text] [Related]
18. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
Kurbel S
Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
[TBL] [Abstract][Full Text] [Related]
19. [Tumor stem cells in breast cancer].
Ivanov AA; Popova OP; Kuznetsova AV; Danilova TI
Arkh Patol; 2015; 77(5):64-67. PubMed ID: 27077156
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities.
Esparza-López J; Escobar-Arriaga E; Soto-Germes S; Ibarra-Sánchez MJ
Rev Invest Clin; 2017; 69(2):66-76. PubMed ID: 28453505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
